HCA Healthcare
HCA
$445.01
+1.33%
HCA Healthcare, Inc. is the largest for-profit acute-care hospital operator in the United States, running 190 hospitals and more than 2,500 outpatient facilities across 19 states, with a small international foothold in the United Kingdom, serving patients primarily through Medicare, Medicaid, and managed care payors. Its scale, dense urban cluster strategy, and vertically integrated outpatient network make it the dominant platform in the medical-care-facilities industry, distinct from smaller peers like Tenet Healthcare and Community Health Systems. The current investor narrative is a tug-of-war between resilient core operations — Q2 2026 revenue of $20.23 billion grew 8.7% year over year with EPS of $7.62 — and persistent policy overhangs around Medicaid supplemental payments, uninsured admissions mix, and reimbursement pressure, themes echoed in recent industry headlines about unfavorable patient insurance mix. Bulls point to an aging U.S. population and HCA's aggressive capital-return program (over $2 billion of buybacks in Q2 2026 alone) as long-term drivers, while bears focus on the stock's 9.3% YTD decline and negative shareholder equity that distorts traditional balance-sheet metrics.…
HCA
HCA Healthcare
$445.01
Related headlines
Investment Opinion: Should I buy HCA Today?
HCA Healthcare is rated a Hold with a balanced risk/reward profile. The core thesis is that HCA's dominant scale, consistent 8.73% revenue growth, and discounted valuation (forward PE of 13.33x, PEG of 0.57) are offset by policy overhangs and relative underperformance versus the market. The analyst consensus is 'buy' with an average target price of $454.23, implying roughly +6.5% upside from the current $426.69, but the wide target range ($380-$579) and mixed ratings (Morgan Stanley Underweight, JP Morgan Neutral) suggest limited near-term conviction.
Supporting evidence for the Hold rating includes: (1) revenue growth of 8.73% year over year in Q2 2026, with no deceleration; (2) EBITDA margin expansion to 19.83% from 19.27% a year earlier; (3) strong free cash flow of $6.00 billion TTM, funding $2.06 billion of buybacks and $171 million of dividends in Q2 2026; and (4) a forward PE of 13.33x, which is below the broader healthcare sector's mid-to-high teens and the stock's own historical range. However, the 0.83 current ratio and negative equity are watch items, and the 15.01 percentage point relative underperformance versus SPY over the past year reflects these concerns.
The biggest risks that could invalidate the thesis are: (1) a deterioration in payor mix or cuts to Medicaid supplemental payments that compress margins below 8%; (2) a breakdown below the 52-week low of $353.99, which would signal a deeper bearish trend; and (3) a broader market rotation away from healthcare. The rating would upgrade to Buy if the stock reclaims the mid-$450s and reimbursement clarity improves, or downgrade to Sell if revenue growth decelerates below 5% or EBITDA margins fall below 18%. Relative to its history and peers, HCA appears fairly valued to slightly undervalued, but the policy overhang justifies a cautious stance.
Sign up to view all
HCA 12-Month Price Forecast
HCA presents a balanced risk/reward profile with a neutral stance. The company's operational execution is strong, with consistent revenue growth and expanding EBITDA margins, and the valuation is attractive on a PEG basis. However, policy overhangs and payor-mix deterioration pose significant risks, and the stock's relative underperformance versus the market reflects these concerns. The analyst consensus is cautiously bullish, but the wide target range and mixed ratings indicate limited conviction. I would upgrade to bullish if reimbursement clarity improves and the stock reclaims the mid-$450s, or downgrade to bearish if margins compress below 18% or revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Healthcare's 12-month outlook, with a consensus price target around $459.27 and implied upside of +3.2% versus the current price.
Average Target
$459.27
0 analysts
Implied Upside
+3.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$380 - $579
Analyst target range
Coverage is broad and institutional, with 22 analysts and a consensus recommendation of "buy" (mean rating 1.96 on a 1-to-5 scale where lower is more bullish). The average target price of $454.23 implies roughly +6.5% upside from the current $426.69, a modest but positive expected return, and consensus revenue estimates of $96.29 billion with EPS estimates of $44.81 underpin the constructive stance. Sentiment is best characterized as cautiously bullish: the buy rating is supported by recent reiterations from Goldman Sachs (Buy), UBS (Buy), RBC Capital (Outperform), Leerink (Outperform), Mizuho (Outperform), and Truist (Buy), but the presence of Morgan Stanley at Underweight and JP Morgan and Wells Fargo at Neutral/Equal Weight shows meaningful skepticism about the policy and payor-mix outlook. The target range is wide — $380 low to $579 high, a spread of $199, or roughly 47% of the current price — which signals high uncertainty rather than strong conviction. The $579 high target implies multiple expansion and successful navigation of reimbursement headwinds, effectively pricing HCA back toward its 52-week high of $556.52 and a mid-teens forward PE on peak-cycle earnings, while the $380 low target implies margin compression and payor-mix deterioration that would push the stock toward its 52-week low of $353.99. Notably, the institutional ratings flow shows no upgrades or downgrades in the recent record — every firm reiterated its existing stance — suggesting analysts are in a holding pattern awaiting clarity on Medicaid supplemental payments and admission trends before repositioning.
Drowning in data?
Find the real signal!
Bulls vs Bears: HCA Investment Factors
The bear case currently has stronger evidence due to HCA's 15.01 percentage point relative underperformance versus SPY over the past year, a 9.29% YTD decline, and persistent policy overhangs around Medicaid supplemental payments and payor mix. However, the bull case is supported by solid operational execution — 8.73% revenue growth, expanding EBITDA margins, and a PEG ratio of 0.57 — suggesting the stock is cheap relative to its growth. The single most important tension is whether reimbursement headwinds and unfavorable patient insurance mix will compress margins enough to justify the current de-rating, or whether HCA's scale and capital-return program can drive a re-rating toward the analyst average target of $454.23. Near-term momentum has turned constructive (+6.13% 1-month), but the advance lacks aggressive institutional conviction on light volume. Resolution of this debate likely hinges on clarity around Medicaid supplemental payments and admission trends.
Bullish
- Revenue growth accelerating with scale: Q2 2026 revenue of $20.23 billion grew 8.73% year over year from $18.61 billion, and the sequential progression from $19.11 billion in Q1 2026 to $20.23 billion shows no deceleration. The multi-quarter trend from $17.49 billion in Q3 2024 to $19.16 billion in Q3 2025 to $20.23 billion in Q2 2026 reflects consistent mid-to-high single-digit organic growth.
- Profitability expanding despite margin optics: Q2 2026 net income was $1.70 billion on an 8.40% net margin, while EBITDA rose to $4.01 billion (19.83% EBITDA margin) from $3.85 billion a year earlier. Operating margin of 15.83% and trailing net margin of 8.97% are healthy for the hospital industry, where single-digit net margins are typical.
- Deep valuation discount with PEG 0.57: HCA trades at a trailing PE of 16.31x and a forward PE of 13.33x, with a PEG ratio of 0.57, suggesting the stock is cheap relative to its expected EPS growth. EV/EBITDA of 10.05x is a discount to the market's ~15x average and to many large-cap healthcare peers.
- Aggressive capital return and FCF: Q2 2026 operating cash flow of $2.34 billion against $1.23 billion of capex yielded $1.10 billion of quarterly free cash flow and $6.00 billion TTM. The company returned $2.06 billion of buybacks and $171 million of dividends in Q2 2026 alone, reducing shares outstanding from 241.9 million to 222.8 million year over year.
Bearish
- Severe relative underperformance vs. SPY: HCA has posted a 0.0% 1-year price change versus a 15.01% gain for SPY, a relative-strength gap of -15.01 percentage points. The 6-month change of -9.57% and YTD decline of -9.29% confirm that the intermediate trend remains corrective despite recent stabilization.
- Policy and payor-mix overhang: Managed care and other insurers contribute $9.01 billion of revenue, but government programs (Medicare $2.93 billion, Medicaid $2.79 billion, managed Medicare $3.42 billion, managed Medicaid $997 million) expose HCA to reimbursement pressure. Recent industry headlines about unfavorable patient insurance mix, such as Tenet Healthcare blaming admissions mix for soft Q1 sales, highlight ongoing headwinds.
- Negative equity distorts balance sheet: Negative shareholders' equity produces an ROE of -112.6% and debt-to-equity of -8.33, artifacts of years of buybacks rather than distress. However, the thin 0.83 current ratio and $1.01 billion cash balance mean liquidity management and continued debt repayment ($1.67 billion in Q2 2026) remain important watch items.
- Wide analyst target range signals uncertainty: The target range is wide — $380 low to $579 high, a spread of $199, or roughly 47% of the current price — which signals high uncertainty rather than strong conviction. The presence of Morgan Stanley at Underweight and JP Morgan and Wells Fargo at Neutral/Equal Weight shows meaningful skepticism.
HCA Technical Analysis
HCA is in a broad range-bound consolidation with a distinctly negative longer-term tilt, having posted a 0.0% 1-year price change versus a 15.01% gain for SPY, a relative-strength gap of -15.01 percentage points. At $426.69, the stock sits at roughly 35.9% of its 52-week range of $353.99 to $556.52, meaning it is trading in the lower-middle portion of its annual band — closer to the low than the high, which signals lingering distribution rather than momentum leadership. The 6-month change of -9.57% and YTD decline of -9.29% confirm that the intermediate trend remains corrective despite recent stabilization. Short-term momentum has turned constructive and is diverging from the longer-term downtrend: the 1-month change of +6.13% and 3-month change of +3.94% both outpace SPY's +0.59% and +3.34% over the same windows, producing positive relative strength of +5.54 (1-month) and +0.60 (3-month). This divergence — improving near-term momentum against a flat-to-negative 1-year trend — is consistent with a base-building or mean-reversion rally off the lows rather than a confirmed trend reversal, and the modest 0.78% single-day gain on light volume of 928,680 suggests the advance lacks aggressive institutional conviction so far. Key technical levels are defined by the 52-week low of $353.99 as major support and the 52-week high of $556.52 as overhead resistance, with the stock needing to reclaim the mid-$450s to challenge the upper half of the range. A breakout above $556.52 would signal a full trend reversal and likely require fundamental catalysts such as reimbursement clarity or accelerating admissions, while a breakdown below $353.99 would confirm the bearish primary trend and open deeper downside. With a beta of 1.109, HCA is roughly 11% more volatile than the market, and its max drawdown of -33.72% over the period underscores that position sizing should account for meaningful capital-at-risk beyond broad market swings.
Beta
1.11
1.11x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$354-$557
Price range past year
Annual Return
+4.4%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +1.0% |
| 3m | +9.4% | +2.5% |
| 6m | -10.2% | +13.9% |
| 1y | +4.4% | +15.0% |
| ytd | -5.4% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
HCA's revenue trajectory remains solidly growth-oriented, with Q2 2026 revenue of $20.23 billion up 8.73% year over year from $18.61 billion in Q2 2025, and the sequential progression from $19.11 billion in Q1 2026 to $20.23 billion in Q2 2026 shows no deceleration. The multi-quarter trend is consistent: quarterly revenue has climbed from $17.49 billion in Q3 2024 to $19.16 billion in Q3 2025 to $20.23 billion in Q2 2026, reflecting mid-to-high single-digit organic growth. Payor mix is the key swing factor — managed care and other insurers contribute $9.01 billion, managed Medicare $3.42 billion, Medicare $2.93 billion, Medicaid $2.79 billion, and managed Medicaid $997 million — so any shift toward lower-reimbursing government programs pressures the growth quality even as headline revenue rises. Profitability is robust and improving: Q2 2026 net income was $1.70 billion on a net margin of 8.40%, up from $1.65 billion and an 8.88% margin in Q2 2025, while gross margin expanded to 15.16% from 15.05% in Q1 2026 and EBITDA rose to $4.01 billion (19.83% EBITDA margin) from $3.85 billion a year earlier. Operating margin of 15.83% and a trailing net margin of 8.97% are healthy for the hospital industry, where single-digit net margins are typical, and the improvement reflects favorable payer rate updates and cost discipline against $8.29 billion of quarterly SG&A. Balance-sheet optics are distorted by negative shareholders' equity — ROE of -112.6% and debt-to-equity of -8.33 are artifacts of years of buybacks rather than distress — but the real risk metrics are more benign: interest coverage of roughly 5.1x, a current ratio of 0.83, and Q2 2026 operating cash flow of $2.34 billion against $1.23 billion of capex, yielding $1.10 billion of quarterly free cash flow and $6.00 billion TTM. The company funds growth internally while returning capital aggressively ($2.06 billion of buybacks and $171 million of dividends in Q2 2026), though the thin 0.83 current ratio and $1.01 billion cash balance mean liquidity management and continued debt repayment ($1.67 billion in Q2 2026) remain important watch items.
Quarterly Revenue
$20.2B
2026-06
Revenue YoY Growth
+8.7%
YoY Comparison
Gross Margin
15.2%
Latest Quarter
Free Cash Flow
$6.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Because HCA is solidly profitable — Q2 2026 net income of $1.70 billion and trailing EPS positive — the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 16.31x versus a forward PE of 13.33x. The 18.3% compression from trailing to forward earnings implies the market expects meaningful EPS growth, consistent with consensus estimated EPS of $44.81 for the coming year, and the PEG ratio of 0.57 suggests the stock is cheap relative to its expected growth rate. Relative to the broader healthcare sector, where hospital and provider names typically trade in the mid-to-high teens on earnings, HCA's 16.3x trailing PE is roughly in line to modestly below the industry average, while its 1.42x PS ratio and 1.87x EV/Sales are undemanding for a business with 8.7% revenue growth. On EV/EBITDA of 10.05x, HCA screens at a discount to the market's ~15x average and to many large-cap healthcare peers, a discount that appears at least partly justified by reimbursement policy risk and the company's leveraged, negative-equity capital structure rather than by inferior operating performance. Historically, HCA's PE has ranged from about 8.0x (Q4 2022) to 20.6x (Q3 2024), with the current 16.31x sitting in the middle-to-upper portion of that band, while its PS ratio of 1.42x is well below the 4.1x–6.0x range seen across 2022–2024 — a discrepancy that reflects the sharp increase in revenue scale and the recent de-rating of the shares. The current multiple therefore embeds neither euphoric optimism nor deep distress: it prices in steady execution with policy risk, leaving room for re-rating if reimbursement headwinds ease, but offering limited cushion if margins compress.
PE
16.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
HCA's financial and operational risks are primarily tied to its leveraged capital structure and payor mix. While interest coverage of roughly 5.1x and $6.00 billion TTM free cash flow provide a cushion, the thin 0.83 current ratio and $1.01 billion cash balance mean liquidity management is critical, especially with $1.67 billion of debt repayment in Q2 2026 alone. Negative shareholders' equity (ROE of -112.6%, debt-to-equity of -8.33) is an artifact of aggressive buybacks but limits financial flexibility if reimbursement pressures intensify. Revenue concentration in government programs — Medicare ($2.93 billion), Medicaid ($2.79 billion), managed Medicare ($3.42 billion), and managed Medicaid ($997 million) — exposes HCA to policy changes, and any shift toward lower-reimbursing programs could pressure the 8.40% net margin. Additionally, the company's growth depends on continued volume increases; a deceleration in admissions or a rise in uninsured patients could quickly erode profitability.
Market and competitive risks include valuation compression if HCA fails to meet growth expectations. At a trailing PE of 16.31x and forward PE of 13.33x, the stock is not expensive relative to its history (which ranged from 8.0x to 20.6x), but the discount to the market's ~15x EV/EBITDA average reflects policy risk. With a beta of 1.109, HCA is roughly 11% more volatile than the market, making it sensitive to macro rotations, especially if interest rates remain elevated and compress healthcare multiples. Competitive threats from smaller peers like Tenet Healthcare and Community Health Systems are less about market share and more about industry-wide payor mix deterioration, as highlighted by Tenet's recent Q1 sales miss due to unfavorable insurance mix. Regulatory headwinds around Medicaid supplemental payments and potential changes to the Affordable Care Act could further pressure reimbursement rates.
The worst-case scenario involves a combination of reimbursement cuts, a shift toward lower-reimbursing government payors, and a broader market de-rating of healthcare stocks. In this scenario, HCA could retest its 52-week low of $353.99, representing a decline of approximately 17% from the current price of $426.69. If margins compress significantly and the analyst low target of $380 is breached, the stock could fall further toward the $350 level, implying a downside of 17-18%. The max drawdown of -33.72% over the period underscores that in a severe downturn, losses could exceed 30% from peak levels. Investors should note that the 52-week low of $353.99 serves as major support; a breakdown below that level would confirm the bearish primary trend and open deeper downside.
FAQ
The key risks include: (1) policy and reimbursement risk, as government programs account for a significant portion of revenue (Medicare $2.93 billion, Medicaid $2.79 billion, managed Medicare $3.42 billion, managed Medicaid $997 million); (2) financial risk from negative equity and a thin 0.83 current ratio, which limit flexibility; (3) competitive and industry risk, as peers like Tenet Healthcare face unfavorable payor mix; and (4) market risk with a beta of 1.109 and a max drawdown of -33.72%. The most severe risk is a cut to Medicaid supplemental payments, which could compress margins and push the stock toward its 52-week low of $353.99.
The 12-month forecast includes a base case (55% probability) with a target range of $430-$470, aligned with the analyst average of $454.23, assuming steady execution and stable margins. The bull case (25% probability) targets $500-$579, driven by favorable reimbursement clarity and margin expansion. The bear case (20% probability) targets $354-$380, reflecting payor-mix deterioration and margin compression. The most likely scenario is the base case, with the key assumption that revenue growth remains in the 6-8% range and EBITDA margins hold above 19%.
HCA appears fairly valued to slightly undervalued. Its trailing PE of 16.31x is in the middle-to-upper portion of its historical range (8.0x to 20.6x), while its forward PE of 13.33x and PEG of 0.57 suggest the market is not pricing in its expected EPS growth. The PS ratio of 1.42x is well below the 4.1x-6.0x range seen in 2022-2024, reflecting the recent de-rating. EV/EBITDA of 10.05x is a discount to the market's ~15x average. The valuation implies the market expects steady execution but with policy risk, leaving room for re-rating if reimbursement headwinds ease.
HCA is a reasonable buy for value-oriented investors with a long-term horizon, but it carries significant policy risk. The stock trades at a forward PE of 13.33x with a PEG of 0.57, and the analyst average target of $454.23 implies about 6.5% upside. However, the 15.01 percentage point underperformance versus SPY over the past year and the 9.29% YTD decline reflect persistent headwinds. The biggest downside risk is a retest of the 52-week low of $353.99, representing roughly 17% downside. For investors comfortable with healthcare policy uncertainty, HCA offers a discounted valuation and strong cash flow; for others, waiting for clarity on reimbursement may be prudent.
HCA is more suitable for long-term investment given its stable cash flows, dividend yield of 0.63%, and exposure to the aging U.S. population. The stock's beta of 1.109 and max drawdown of -33.72% indicate moderate volatility, making it less ideal for short-term trading. The policy overhang and wide analyst target range ($380-$579) suggest that near-term catalysts are uncertain. A minimum holding period of 2-3 years is recommended to allow for reimbursement clarity and the compounding effect of buybacks. Short-term traders might find opportunities around earnings, but the risk/reward favors patient investors.
